• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Ophthalmology

Monthly brolucizumab is noninferior to aflibercept in treating recalcitrant wet age-related macular degeneration

byMolly MunsellandDeepti Shroff Karhade
June 7, 2022
in Ophthalmology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In a phase 3a randomized trial comparing intravitreal brolucizumab to aflibercept for refractory neovascular age-related macular degeneration (nAMD), there was no significant difference between drugs in visual acuity change, and brolucizumab eyes were more likely to be fluid-free at 1 year.

2. Eyes in the brolucizumab group were significantly more likely to have intraocular inflammation than eyes in the aflibercept group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Brolucizumab is one of the newer anti-vascular endothelial growth factor (VEGF) therapies approved for treating neovascular disease of the retina, including neovascular age-related macular degeneration (nAMD). The HAWK and HARRIER trials showed brolucizumab injections every twelve weeks to be superior to other VEGF-targeting therapies such as aflibercept for visual outcomes, but also showed an increased rate of inflammatory complications. This multi-center phase 3a randomized trial, MERLIN, aimed to compare brolucizumab 6 mg to aflibercept 2 mg, both injected every 4 weeks, in the setting of retinal fluid persisting after other anti-VEGF regimens. At week 52, brolucizumab met the primary endpoint of noninferiority to aflibercept in best-corrected visual acuity (BCVA) change, with no significant difference between groups. 40.4% of eyes treated with brolucizumab were free of subretinal and intraretinal fluid at 52 weeks compared to 19.0% treated with aflibercept. However, 9.3% of brolucizumab eyes had intraocular inflammation (IOI) within the year compared to 4.5% of aflibercept eyes. The MERLIN trial was terminated due to this increase in IOI. Brolucizumab is more concentrated than aflibercept and was dosed higher here, which is consistent with both its increased efficacy by some measures here and a higher risk of harmful inflammation. This trial is the first to report on frequent dosing of brolucizumab. The risk of both inflammatory adverse events and all-causes vision loss was unacceptably high with brolucizumab dosed every 4 weeks as a long-term maintenance regimen. However, the outcomes here, particularly the substantial rate of stable fluid-free status in previously refractory eyes, point strongly to a continued role for less frequent brolucizumab in nAMD.

Click to read the study in Ophthalmology

Relevant Reading: Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: A comparative review

In-Depth [randomized controlled trial]: Eyes were randomized in a 2 to 1 ratio to receive brolucizumab or aflibercept, both every 4 weeks for a planned 100 weeks. Adults aged 50 or older treated at 66 sites in the United States between 2018 and 2020 were included. Patients were required to have active nAMD with intraretinal and/or subretinal fluid and to have received at least 7 anti-VEGF injections, most frequently aflibercept, in the previous 9 months with partial but incomplete response. Patients with active IOI at baseline were excluded. The least squares mean difference in BCVA change between brolucizumab and aflibercept was -0.6 letters [95% confidence interval (CI) -2.1­­–0.9]. Eyes receiving brolucizumab had significantly lower central subfield thickness (CST) than aflibercept at 52 weeks. 16.9%, 22.3%, and 35.8% of patients receiving brolucizumab gained ≥15, ≥10, and ≥5 letters, respectively, compared to 17.4%, 20.2%, and 31.5% with aflibercept. 17 total eyes treated with brolucizumab lost ≥15 letters in BCVA at week 52 compared to 3 in the aflibercept group.

RELATED REPORTS

Novel anti-VEGF agent provides additional benefit when combined with ranibizumab for neovascular age-related macular degeneration

Binocular eye tracking-based device is non-inferior to patching for the treatment of amblyopia

Anti-VEGF therapy for retinopathy of prematurity may be associated with pulmonary hypertension risk

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: macular degenerationVEGFvision lossvisual acuity
Previous Post

Prognostic value demonstrated for change of circulating tumour cells and human leukocyte antigen I: programmed cell death-ligand 1 ratio in metastatic renal cell carcinoma

Next Post

Risankizumab induction therapy is effective for moderate-to-severe Crohn’s disease

RelatedReports

Patient Basics: Macular Degeneration
Ophthalmology

Novel anti-VEGF agent provides additional benefit when combined with ranibizumab for neovascular age-related macular degeneration

February 20, 2023
Quick Take: Association of Visual Impairment With Economic Development Among Chinese Schoolchildren
Ophthalmology

Binocular eye tracking-based device is non-inferior to patching for the treatment of amblyopia

November 3, 2022
Cervical conization may double risk of preterm birth
Ophthalmology

Anti-VEGF therapy for retinopathy of prematurity may be associated with pulmonary hypertension risk

October 19, 2022
Roux-en-Y gastric bypass may slow progression of diabetic retinopathy
2 Minute Medicine

Rate of childhood vision screening decreased substantially between 2016 and 2020

October 5, 2022
Next Post
Biosimilar to infliximab shows equivalent safety and efficacy for treating Crohn’s disease

Risankizumab induction therapy is effective for moderate-to-severe Crohn’s disease

Preoperative tumor embolization does not reduce operative blood loss

Tranexamic acid decreases postoperative bleeding in non-cardiac surgery patients

Combined MRI and NIH stroke scores may predict stroke prognosis

Viral meningitis can be differentiated from abusive head trauma with demographic, history, and clinical findings

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Addition of fludrocortisone to hydrocortisone is beneficial in management of septic shock
  • Surveillance testing of staff at nursing facilities reduces resident COVID-19 mortality
  • Childhood maltreatment may cause mental health problems
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options